Form 4 for ENSC Ensysce Biosciences, Inc.

Accepted 2021-07-02 00:00:00 ET · period of report 2021-06-30 · accession 0001192482-21-000620 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-07-02	2021-06-30	ENSC	GOWER BOB G	Dir, 10%	A - Grant	—	+7.92M	7.92M	New	—
D	2021-07-02	2021-06-30	ENSC	GOWER BOB G	Dir, 10%	A - Grant	—	+6,585	6,585	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-06-30	A	A	7,919,026	—	7,919,026	D	—	—	(F1) On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Ensysce common stock was automatically converted into the right to receive a pro rata portion of 17,334,518 shares of the Issuer's common stock.
2	Derivative	Stock Option	2021-06-30	A	A	6,585	—	6,585	D	$2.59 · — to 2029-03-14	6,585 Common Stock	(F2) Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.